Wuxi Biologics Is a Global CRDMO With Near-Term Geopolitical Risks

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations, with its "follow-and-win the molecule" and "global dual-sourcing" strategies. Simply put, it provides end-to-end services for biological drugs from drug discovery all the way to clinical and commercial manufacturing. Unlike its global peers, WuXi specializes in biological therapeutic modalities. It has one of the largest bioreactor capacities with manufacturing sites worldwide. Riding on the structural shift from small molecule drugs to biologic drugs, WuXi has been growing at a compound annual growth rate of 53.3% for the past eight years, much faster than that of global pharmaceutical sales or global CDMOs.